Sonic Healthcare Ltd
SHL: XASX (AUS)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
A$51.00 | Ydfkst | Cvbrdhznx |
Sonic Healthcare Earnings: Shares Undervalued as Margins Recover
Narrow-moat Sonic reported fiscal 2024 underlying organic revenue growth of 6% to AUD 8.9 billion and a group EBITDA of AUD 1.6 billion, both meeting our expectations. The result was driven by strong organic sales growth in Australia and Europe. Although recent acquisitions and cost pressures have weighed on group profitability, the second-half group EBITDA margin expanded roughly 150 basis points on the first half to 18.6% on margin improvement initiatives.